Quantitative proteomic determination of diethylstilbestrol action on prostate cancer

Asian Journal of Andrology

Volumn 15, Issue 3, 2013, Pages 413-420

  Bigot, Pierre ^a,b   Mouzat, Kevin ^b,c   Lebdai, Souhil ^a   Bahut, Muriel ^d   Benhabiles, Nora ^e   Tassin, Géraldine Cancel ^b   Azzouzi, Abdel Rahmène ^a   Cussenot, Olivier ^b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b HÔPITAL TENON   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ D'ANGERS   (France)

^e INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Cultured cells; DES; Diethylstilbestrol; Ingenuity pathway analysis; Isotope labelling; Mass spectrometry; Prostate cancer; Proteomics

Indexed keywords

DIETHYLSTILBESTROL; PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL DIFFERENTIAL IN GEL ELECTROPHORESIS;

CELL LINE, TUMOR; DIETHYLSTILBESTROL; ESTROGENS, NON-STEROIDAL; GENE EXPRESSION; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; ORNITHINE-OXO-ACID TRANSAMINASE; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS;

EID: 84877292422     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2012.128     Document Type: Article

References (41)

1. Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 2008; 44: 928-36.
2. Scherr DS, Pitts WR Jr. The nonsteroidal effects of diethylstilbestrol: The rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003; 170: 1703-8.
3. Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F et al. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormonereleasing hormone analogues and orchidectomy. BJU Int 2000; 85: 1069-73.
4. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman Met al. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 257-60.
5. Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer 2003; 98: 1603-10.
6. Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M et al. Diethylstilbestrol and docetaxel: A Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 2007; 110: 996-1002.
7. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-30.
8. Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 2002; 1: 81-9.
9. Bosset PO, Albiges L, Seisen T, de la Motte Rouge T, Phe V et al. Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int; e-pub ahead of print May 2012; doi: 10.1111/j.1464-410X.2012.11206.x.
10. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001; 58: 108-13.
11. Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996; 88: 908-17.
12. Koike H, Ito K, Takezawa Y, Oyama T, Yamanaka H et al. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer. Br J Cancer 2005; 92: 1538-44.
13. Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 2010; 12: 639-57.
14. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6.
15. Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35: 403-9.
16. Comuzzi B, Sadar MD. Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cellscience 2006; 3: 61-81.
17. Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD et al. Ex PASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 2003; 31: 3784-8.
18. Lefever S, Vandesompele J, Speleman F, Pattyn F. RTPrimer DB: the portal for realtime PCR primers and probes. Nucleic Acids Res 2009; 37: D942-5.
19. Huggins CB, Hodges CV. Studies on prostate cancer: the effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
20. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 2012; 31: 4759-67.
21. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 79-92.
22. Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993; 17: 263-5.
23. Wu WW, Wang G, Baek SJ, Shen RF. Comparative study of three proteomic quantitative methods, DIGE, c ICAT, and i TRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006; 5: 651-8.
24. Cipolla BG, Ziade J, Bansard JY, Moulinoux JP, Staerman F et al. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma. Cancer 1996; 78: 1055-65.
25. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; 243: C212-21.
26. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE et al. Expression of arginase II in prostate cancer. Int J Oncol 2008; 32: 357-65.
27. Mueckler MM, Moran S, Pitot HC. Transcriptional control of ornithine aminotransferase synthesis in rat kidney by estrogen and thyroid hormone. J Biol Chem 1984; 259: 2302-5.
28. Konishi H, Matsuzaki H, Tanaka M, Takemura Y, Kuroda S et al. Activation of protein kinase B (Akt/RAC-protein kinase) by cellular stress and its association with heat shock protein Hsp27. FEBS Lett 1997; 410: 493-8.
29. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP et al. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. Faseb J 1999; 13: 2061-70.
30. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000; 2: 645-52.
31. Adams DJ, Edwards DP, McGuire WL. Estrogen regulation of specific proteins as a mode of hormone action in human breast cancer. Biomembranes 1983; 11: 389-414.
32. Foster CS, Dodson AR, Ambroisine L, Fisher G, Moller H et al. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer 2009; 101: 1137-44.
33. Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. Apmis 2008; 116: 888-95.
34. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 2010; 28: 145-51.
35. Grotendorst GR, Lau LF, Perbal B. CCN proteins are distinct from and should not be considered members of the insulin-like growth factor-binding protein superfamily. Endocrinology 2000; 141: 2254-6.
36. Jenkins PJ, Bustin SA. Evidence for a link between IGF-I and cancer. Eur J Endocrinol/Eur Federat Endocrine Soc 2004; 151 (Suppl 1): S17-22.
37. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: 461-71, W83-8.
38. Degraff DJ, Malik M, Chen Q, Miyako K, Rejto L et al. Hormonal regulation of IGFBP-2 proteolysis is attenuated with progression to androgen insensitivity in the LNCa P progression model. J Cellular Physiol 2007; 213: 261-8.
39. Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A et al. Insulin-like growth factorbinding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 104: 1587-93.
40. Geier R, Adler S, Rashid G, Klein A. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells. Prostate 2010; 70: 1307-12.
41. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000; (27): 75-93.